AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32419303
Drug: Exercise combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise combined with education and manual therapy
Trial: 33973923
Drug: Bup/Nal treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bup/Nal treatment for 12 weeks
Trial: 33973923
Drug: Detox treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detox treatment for up to 2 weeks
Trial: 33341406
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg CaEDTA in Tris‐buffered saline nebulised with 250 mg tobramycin
Trial: 33341406
Drug: Placebo (Tris‐buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Tris‐buffered saline) nebulised with 250 mg tobramycin
Trial: 35035537
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with ‘step-up’ DMARD therapy
Trial: 35035537
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy with NSAIDs and local corticosteroid injections
Trial: 32022863
Drug: Once-weekly placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly placebo
Trial: 35915506
Drug: Extended-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release guanfacine (GXR)
Trial: 615709281
Drug: Cannabis (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis (54 mg) administered orally
Trial: 615709281
Drug: THC (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (3 and 10 mg/kg) administered to mice
Trial: 34569871
Drug: Picture-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picture-based medication calendar
Trial: 34165835
Drug: Four implants
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four implants in maxillary overdentures
Trial: 34165835
Drug: Denture supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denture supported by four implants
Trial: 34165835
Drug: Two implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two implants in mandibular overdentures
Trial: 34726230
Drug: Recombinant hGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hGH treatment (various doses)
Trial: 34464358
Drug: High-dose convalescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose convalescent plasma (3 units) plus standard treatment
Trial: 38066597
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment alone)
Trial: 34464358
Drug: Higher cumulative
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher cumulative amount of neutralizing antibodies plus standard treatment
Trial: 34314402
Drug: Volar plate
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volar plate fixation (operative treatment)
Trial: 34314402
Drug: Cast immobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cast immobilization (nonoperative treatment)
Trial: 35546018
Drug: ICS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS treatment
Trial: 33834608
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg L-Cystine and 250 mg L-Glutathione
Trial: 33834608
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg reduced L-Glutathione
Trial: 33834608
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg L-Cystine
Trial: 34156693
Drug: RefluG™ (galactomannan-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RefluG™ (galactomannan-based formulation), one sachet three times per day for 14 days
Trial: 32086918
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides Farinae
Trial: 33767795
Drug: 1% Satureja
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Satureja khuzestanica vaginal cream
Trial: 33767795
Drug: 1% clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clotrimazole vaginal cream
Trial: 37679711
Drug: ACAT program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACAT program and treatment‐as‐usual
Trial: 37679711
Drug: treatment‐as‐usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment‐as‐usual
Trial: 33789610
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (200 ml IV at 100 ml/h)
Trial: 33789610
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 ml IV)
Trial: 32867282
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of omega‐3 long chain polyunsaturated fatty acids (n‐3 LCPUFA) and multivitamin supplements
Trial: 36239645
Drug: Thrombectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombectomy plus medical therapy
Trial: 36239645
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy only (control)
Trial: 32051083
Drug: Concerta treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concerta treatment
Trial: 32051083
Drug: Strattera treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strattera treatment
Trial: 37660037
Drug: Pivmecillinam 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 400 mg three times daily and amoxicillin/clavulanic acid 500/125 mg three times daily for 10 days
Trial: 37660037
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 500 mg twice daily or oral trimethoprim–sulfamethoxazole 800 mg/160 mg twice daily or intravenous ertapenem 1 g once daily for 7–10 days
Trial: 32031091
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg of dexmedetomidine in 0.3 ml of normal saline (Group D)
Trial: 32031091
Drug: 0.3 ml
RxNorm normalized name: ethanol 0.3 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml of normal saline alone (Group S)
Trial: 32212997
Drug: Laparoscopic-Assisted Extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic-Assisted Extracorporeal Ureteral Tapering Repair (EUTR)
Trial: 32772395
Drug: Single-implant (G-I)
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-implant (G-I)
Trial: 32772395
Drug: Two-implant overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant overdentures (G-II)
Trial: 32772395
Drug: Fixed 4-implant
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed 4-implant complete denture (G-III)
Trial: 35713772
Drug: Osimertinib adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib adjuvant therapy
Trial: 32605447
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg cannabidiol
Trial: 32605447
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cannabidiol
Trial: 35241098
Drug: CoQ10 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (120 mg)
Trial: 34247263
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) 5 mg intravenous infusion once yearly for 2 years
Trial: 32076362
Drug: Moderation-based alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderation-based alcohol treatment with naltrexone and Modified Behavioral Self-Control Training
Trial: 35180190
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester (KME; 0.5 g·kg‐1)
Trial: 34261858
Drug: Eflornithine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine (750 mg) + Sulindac (150 mg)
Trial: 34261858
Drug: Sulindac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (150 mg)
Trial: 34261858
Drug: Eflornithine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine (750 mg)
Trial: 32915063
Drug: Antibacterial envelope
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial envelope (TYRX) adjunctive to standard-of-care infection prevention
Trial: 35501751
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (15 mg/kg before incision and 1 mg/kg/hour during operation)
Trial: 35501751
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo: 0.9% sodium chloride solution)
Trial: 34555333
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg every 21 days for 16 cycles or 1 year)
Trial: 34909951
Drug: Oxybutynin 5
RxNorm normalized name: oxyBUTYnin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5 mg/day (Group O)
Trial: 34909951
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg/day (Group M)
Trial: 33517316
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with anthracycline followed by paclitaxel, RDI ≥85%
Trial: 33517316
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with anthracycline followed by paclitaxel, RDI <85%
Trial: 33071237
Drug: PRT +
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PRT + metformin (metPRT)
Trial: 35079806
Drug: Nutrient compendium
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient compendium snacks containing ≥5 g fiber, 1000 mg ω‐3 fatty acids, 1000 mg phytosterols, and 1800 μmol antioxidants per serving.
Trial: 34399585
Drug: Antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drug classes
Trial: 34399585
Drug: Lipid-lowering drug
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drug classes
Trial: 34399585
Drug: Anticoagulant drug
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant drug classes
Trial: 34399585
Drug: Novel drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel drug targets for inflammatory pathways
Trial: 34399585
Drug: Novel drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel drug targets for coagulation cascade
Trial: 33408462
Drug: Half-dose triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + chlorthalidone 6.25 mg)
Trial: 33408462
Drug: Third-dose triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-dose triple combination (amlodipine 1.67 mg + losartan 16.67 mg + chlorthalidone 4.17 mg)
Trial: 33408462
Drug: Quarter-dose triple
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarter-dose triple combination (amlodipine 1.25 mg + losartan 12.5 mg + chlorthalidone 3.13 mg)
Trial: 35835521
Drug: Soft palatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft palatal augmentation prosthesis (PAP)
Trial: 33745452
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue (1 cc of IFABOND® applied to the surgical bed)
Trial: 33008699
Drug: Three-dimensional printed
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dimensional printed ear splint therapy
Trial: 35332042
Drug: Clinicians' routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinicians' routine treatment procedures
Trial: 32829596
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy combined with vestibular rehabilitation training (Experimental group)
Trial: 32829596
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (Control group)
Trial: 32295565
Drug: Minocycline as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline as adjunctive treatment
Trial: 36191986
Drug: ICIs plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICIs plus chemotherapy (chemoimmunotherapy)
Trial: 36191986
Drug: ICIs plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICIs plus chemotherapy (chemoimmunotherapy) with prior brain radiotherapy
Trial: 34497852
Drug: Dapagliflozin adjunct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin adjunct to continuous subcutaneous insulin infusion (CSII)
Trial: 32859666
Drug: Remote support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote support for therapy programme
Trial: 33060179
Drug: Identification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identification of biological motion (BM) actions by the CC group
Trial: 33060179
Drug: Coherent motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coherent motion (CM) detection task by the CC group
Trial: 35572961
Drug: Electro-Thumbtack Needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-Thumbtack Needle (ETN) therapy administered three times a week for four consecutive weeks
Trial: 35572961
Drug: Sham ETN
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ETN therapy administered three times a week for four consecutive weeks
Trial: 35572961
Drug: Electro-Thumbtack Needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-Thumbtack Needle (ETN) therapy
Trial: 35572961
Drug: Sham ETN
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ETN therapy
Trial: 33214593
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SAP P11‐4 and delayed FV after 90 days
Trial: 35783486
Drug: Trimer 4571
RxNorm normalized name: glyoxal trimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimer 4571 adjuvanted with 500 mcg alum, administered subcutaneously or intramuscularly at weeks 0, 8, and 20 in doses of 100 mcg or 500 mcg
Trial: 34237271
Drug: RO7049389 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049389 200 mg twice a day
Trial: 34237271
Drug: RO7049389 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049389 400 mg twice a day
Trial: 34237271
Drug: RO7049389 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049389 200 mg once a day
Trial: 34237271
Drug: RO7049389 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049389 600 mg once a day
Trial: 34237271
Drug: RO7049389 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049389 1000 mg once a day
Trial: 35687059
Drug: Norepinephrine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine bolus at 0.10 μg/kg
Trial: 35687059
Drug: Norepinephrine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine bolus at 0.05 μg/kg
Trial: 32876804
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (2000 mg/day)
Trial: 34844551
Drug: Secnidazole 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole 2.0 g po followed by Azithromycin 500 mg on day 1 continuing by 250 mg on days 2-7
Trial: 34844551
Drug: Secnidazole 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole 2.0 g po followed by Josamycin 1000 mg bid for 12 days
Trial: 34844551
Drug: Secnidazole 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole 2.0 g po followed by Moxifloxacin 400 mg once daily for 12 days
Trial: 34047715
Drug: Home-centered activity-based
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-centered activity-based therapy (parent-supervised) in addition to institutional physiotherapy
Trial: 32287316
Drug: P60.4Ac-containing ototopical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P60.4Ac-containing ototopical drops (0.25-2.0 mg of peptide/ml)
Trial: 32853646
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment phase
Trial: 33159256
Drug: High-dose mizoribine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mizoribine (MZR) pulse therapy combined with steroid treatment
Trial: 33159256
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment of steroid combined with cyclophosphamide (CPM)
Trial: 33763699
Drug: Ixazomib 4
RxNorm normalized name: ixazomib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib 4 mg plus lenalidomide and dexamethasone (Rd)
Trial: 34106753
Drug: Best supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care or hypomethylating therapy in the No-Donor arm
Trial: 32448171
Drug: Metastasis-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastasis-directed therapy to all visible progressive lesions
Trial: 34183429
Drug: iGlarLixi (once-daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlarLixi (once-daily)
Trial: 34183429
Drug: BIAsp 30
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BIAsp 30 (twice-daily)
Trial: 32408108
Drug: Laxative escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative escalation criteria.
Trial: 32408108
Drug: Discontinuation criteria
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation criteria for bowel protocols.
Trial: 32352642
Drug: Plasma retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma retinol levels <58.3 μg/dL
Trial: 32352642
Drug: Plasma retinol
RxNorm normalized name: retinol
DrugBank: Vitamin A (DB00162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma retinol levels ≥58.3 μg/dL
Trial: 32352642
Drug: Higher time-averaged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher time-averaged SBP (≥140 mm Hg) in participants with plasma retinol <58.3 μg/dL
Trial: 32352642
Drug: Higher vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher vitamin E levels (≥11.5 μg/mL) in participants with plasma retinol <58.3 μg/dL
Trial: 35880280
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (balance acupotomy + warm needling)
Trial: 32230987
Drug: Metronidazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (400 mg twice daily in Week 1) followed by Inulin (4 g twice daily)
Trial: 32230987
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily in Week 1) followed by Inulin
Trial: 33788480
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (acupuncture, moxibustion, Chinese herbal medicine, and western medication)
Trial: 33788480
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (clomiphene citrate, chorionic gonadotrophin, and aspirin)
Trial: 32780258
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) received tablets with starch
Trial: 36235570
Drug: BCAA (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (8 g)
Trial: 36235570
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (7.5 g)
Trial: 32822692
Drug: Early or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early or late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL) among mothers with asthma
Trial: 32822692
Drug: Early and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early and late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL) among mothers with asthma
Trial: 32822692
Drug: Early or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early or late prenatal vitamin D sufficiency (25(OH)D level ≥ 30 ng/mL)
Trial: 32338067
Drug: Glycine max
RxNorm normalized name: Glycine max oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine max (L.) Merr isoflavone 4% vaginal gel